

PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

Buscopan[®] Compositum



Boehringer
Ingelheim

Spasmolytic and Analgesic

Active Constituents

500 mg/mL dipyrone

4 mg/mL hyoscine-N-butylbromide

Indications

Assists in the treatment of gastro-enteritis.

Spasm of the gastro-intestinal, biliary or urogenital tracts associated with severe pain.

Buscopan[®] compositum relieves both pain and smooth muscle spasm.

Horses/Foals

Spasmodic colic, scours, oesophageal obstruction, enteritis with diarrhoea.

Dogs

Colic, gastroenteritis with diarrhoea, vomiting, spasm of the urogenital tract, pain associated with digestive disturbances, tenesmus, urinary calculi.

In gastroenteritis Buscopan[®] compositum can be used in combination with antibiotics, sulphonamides or anthelmintics, as required.

Net contents

100 mL

Directions for use

Dosage and Administration

Horses: 20–30 mL intravenously.

Foals: 5–10 mL intravenously.

Dogs: 1–2.5 mL subcutaneously or intravenously.

Intravenous injection to be given slowly.

The injection may be repeated after 4 hours if necessary.

General directions

Activity:

Buscopan[®] compositum acts in three ways:

- directly as a spasmolytic
- directly as an analgesic
- indirectly as an anti-inflammatory agent

These three actions are interrelated.

Pharmacology:

Buscopan[®] blocks the transmission of neural stimuli at the intramural ganglia of the hollow abdominal organs, which are innervated by the parasympathetic nervous system.

Absorption and distribution studies established that Buscopan[®] compositum is concentrated in the walls of the hollow abdominal organs causing a spasmolysis. This accounts for the lack of systemic atropine like side-

effects. Buscopan® remains mainly in the enterohepatic circulation. Dipyrrone has central analgesic activity plus a direct effect on the smooth muscle cells, lowering the excitability of the smooth muscle fibres.

This latter effect together with dipyrrone's anti-inflammatory action, enhances the properties of Buscopan®. Dipyrrone is well tolerated parenterally.

Clinical Action:

Buscopan® compositum is recommended in all conditions of severe pain involving spasm in the gastrointestinal, biliary and urogenital tracts. With intravenous administration pain often recedes before the injection is completed and pain relief is clearly apparent. The injection may be repeated after four hours if necessary. The duration of action is approximately six hours.

Buscopan® compositum brings about relief of colic by abolishing the spasm and relieving the pain ensuring a rapid return to normal peristalsis and intestinal function.

Enteritis associated with scouring quickly debilitates the animal through excessive fluid loss. Buscopan® compositum normalises intestinal tone and function, preventing further fluid loss. Concurrent treatment with an appropriate antibacterial or anthelmintic may be instituted. Clinical reports confirm Buscopan® compositum's usefulness of colic in horses and gastroenteritis in small animals.

WITHHOLDING PERIODS
MEAT WITHHOLDING PERIOD
(HORSES): DO NOT USE less than 28 days before slaughter for human consumption.

FIRST AID

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Disposal

Dispose of empty container by wrapping with paper and putting in garbage.

Storage

Store below 25°C (air conditioning). After opening, the colour of the injection solution may change. This does not influence efficacy.

Presentation

100 mL bottle, solution for injection.

Boehringer Ingelheim Pty Limited
Animal Health Division
78 Waterloo Road
NORTH RYDE NSW 2113
Phone: 1800 038 037
www.boehringer-ingelheim.com.au

APVMA 53006/105371